---
figid: PMC6361575__CAS-110-481-g003
figtitle: Smad3 linker phosphorylation negatively regulates transforming growth factor‐B
  (TGF‐B)/Smad3 signaling
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Homo sapiens
- Mus musculus
- Danio rerio
pmcid: PMC6361575
filename: CAS-110-481-g003.jpg
figlink: /pmc/articles/PMC6361575/figure/cas13922-fig-0003/
number: F3
caption: Smad3 linker phosphorylation negatively regulates transforming growth factor‐β
  (TGF‐β)/Smad3 signaling. Blockade of Smad3 linker phosphorylation (shown as ××××)
  by Smad3 mutant at linker phosphorylation sites (EPSM) markedly intensifies TGF‐β‐induced
  epithelial‐mesenchymal transition (EMT) as well as Smad3 transcriptional activation,
  indicating that Smad3 linker phosphorylation suppresses TGF‐β responses (shown by
  a hammer‐headed line under the word Linker). Although the Smad3 pathway plays a
  principal role in TGF‐β‐induced EMT, cooperation of the non‐Smad3 signaling pathways
  is indispensable for target gene expression. Transcriptional cofactors that form
  complexes with Smad3 are activated through Wnt/glycogen synthase kinase‐3β (GSK‐3β),
  Ras/ERK, p38, JNK, and PI3K/Akt pathways. EMT‐promoting transcriptional cofactors
  include Snail, Zeb, Twist, β‐catenin, AP‐1, Foxc2, TCF, and SP1. They are required
  for suppression of epithelial markers, such as E‐cadherin and upregulation of mesenchymal
  markers, such as vimentin (not shown). Arrow‐ and hammer‐headed lines represent
  activation and inhibition, respectively, in signaling pathways. Upward arrow‐headed
  line (red) indicates augmentation of TGF‐induced EMT, metastasis, and invasion by
  mutation of Smad3 linker phosphorylation sites; CDK, cyclin‐dependent kinase; EGF,
  epidermal growth factor; FGF, fibroblast growth factor; HGF, hepatocyte growth factor;
  IGF, insulin‐like growth factor; PDGF, platelet‐derived growth factor
papertitle: Phosphorylation status at Smad3 linker region modulates transforming growth
  factor‐β‐induced epithelial‐mesenchymal transition and cancer progression.
reftext: Akira Ooshima, et al. Cancer Sci. 2019 Feb;110(2):481-488.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8376361
figid_alias: PMC6361575__F3
figtype: Figure
redirect_from: /figures/PMC6361575__F3
ndex: 94eb6c6b-df22-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6361575__CAS-110-481-g003.html
  '@type': Dataset
  description: Smad3 linker phosphorylation negatively regulates transforming growth
    factor‐β (TGF‐β)/Smad3 signaling. Blockade of Smad3 linker phosphorylation (shown
    as ××××) by Smad3 mutant at linker phosphorylation sites (EPSM) markedly intensifies
    TGF‐β‐induced epithelial‐mesenchymal transition (EMT) as well as Smad3 transcriptional
    activation, indicating that Smad3 linker phosphorylation suppresses TGF‐β responses
    (shown by a hammer‐headed line under the word Linker). Although the Smad3 pathway
    plays a principal role in TGF‐β‐induced EMT, cooperation of the non‐Smad3 signaling
    pathways is indispensable for target gene expression. Transcriptional cofactors
    that form complexes with Smad3 are activated through Wnt/glycogen synthase kinase‐3β
    (GSK‐3β), Ras/ERK, p38, JNK, and PI3K/Akt pathways. EMT‐promoting transcriptional
    cofactors include Snail, Zeb, Twist, β‐catenin, AP‐1, Foxc2, TCF, and SP1. They
    are required for suppression of epithelial markers, such as E‐cadherin and upregulation
    of mesenchymal markers, such as vimentin (not shown). Arrow‐ and hammer‐headed
    lines represent activation and inhibition, respectively, in signaling pathways.
    Upward arrow‐headed line (red) indicates augmentation of TGF‐induced EMT, metastasis,
    and invasion by mutation of Smad3 linker phosphorylation sites; CDK, cyclin‐dependent
    kinase; EGF, epidermal growth factor; FGF, fibroblast growth factor; HGF, hepatocyte
    growth factor; IGF, insulin‐like growth factor; PDGF, platelet‐derived growth
    factor
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - EGF
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - HGF
  - IL6
  - SOS1
  - IGF1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - TGFB1
  - TGFB2
  - TGFB3
  - KRAS
  - HRAS
  - NRAS
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - EPHB2
  - MAPK3
  - AKT1
  - AKT2
  - AKT3
  - MAPK8
  - MAPK9
  - MAPK10
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - GSK3B
  - SMAD3
  - SMAD4
  - SNAI1
  - TWIST1
  - CTNNB1
  - LEF1
  - HNF4A
  - SP1
  - PSG1
  - DAND5
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - FOXC2
  - ITK
  - SLC22A3
  - Egf
  - Hgf
  - Met
  - Tgfb1
  - Ltbp1
  - ras
  - Hras
  - Kras
  - Rem1
  - Crk
  - Grap2
  - Syp
  - Mapk14
  - Ahsa1
  - Ephb2
  - Mapk1
  - Akt1
  - Mapk8
  - Pik3r1
  - Gsk3b
  - Scn5a
  - Scn4a
  - Smad3
  - Smad4
  - Zeb1
  - Snai1
  - Twist1
  - Ctnnb1
  - Lef1
  - Sp1
  - Jun
  - Foxc2
  - Itk
  - Slc22a3
  - egf
  - celsr1a
  - igfn1.2
  - kita
  - ngfra
  - rab1ab
  - mapk14a
  - mapk8b
  - gsk3ba
  - smad3a
  - smad4a
  - smad4b
  - snai1a
  - ctnnb1
  - lef1
  - elk4
  - sp1
  - mt
  - Metastasis
---
